Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$14.60M
• Dividend Yield: N/A
• Average Volume (3M): 73.07K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.34
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 81,691
• 30 Day Avg. Volume: 73,070
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by significant financial challenges, including declining revenues and profitability issues, which are the most critical factors. Technical analysis shows some positive trends, but these are overshadowed by poor valuation metrics, including a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc (BLAB) is a biotechnology company focused on the research, development, and commercialization of innovative therapies and diagnostics in the life sciences sector. The company specializes in advanced healthcare solutions, including molecular diagnostics, personalized medicine, and therapeutic drug development, aimed at improving patient outcomes and advancing health care practices globally.

How the Company Makes Money

Britannia Life Sciences Inc generates revenue through multiple streams, primarily from the sale of proprietary diagnostic products, licensing agreements for its patented technologies, and collaborations with pharmaceutical companies for drug development. The company also earns income from research grants and funding, as well as strategic partnerships that enhance its product offerings and market reach. Significant collaborations with health institutions and industry partners further bolster its revenue by providing access to broader markets and shared resources.

Britannia Life Sciences Inc Financial Statement Overview

Summary

Britannia Life Sciences Inc faces significant financial challenges, with declining revenues and profitability issues. The balance sheet shows high leverage, although recent improvements in equity and net income are positive signs. Cash flow remains a concern, with negative operating cash flow indicating potential liquidity constraints. Overall, the company needs to address these issues to stabilize and improve its financial health.

Income Statement

The income statement reveals significant challenges, with negative revenue growth and fluctuating profit margins. The TTM data shows a drastic revenue decline, and net profit margins are negative, indicating profitability issues. However, there is a positive net income in the latest TTM, which is a slight improvement.

Balance Sheet

The balance sheet shows a mixed picture with a manageable debt-to-equity ratio in the TTM, but historical data indicates high leverage and negative equity in some periods. The return on equity has improved recently, but overall stability remains a concern due to fluctuating equity levels.

Cash Flow

Cash flow analysis highlights negative operating cash flow and free cash flow in the TTM, with some improvement in free cash flow growth. The ratios indicate cash flow challenges relative to net income, suggesting potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-1.23M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-1.14M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.73M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	7.44M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	9.81M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	6.14M	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	1.82M	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	4.26M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	5.55M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-3.98M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-3.78M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	11.11M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.68M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Neutral. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.09, and above the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.34 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$14.60M	―	―	―	-3.93%	-575.24%
KNE	41 Neutral	C$4.99M	-2.19	―	―	―	―
BIOV	29 Underperform	$7.43M	-1.15	―	―	―	25.09%
BETR	21 Underperform	C$8.35M	―	―	―	―	85.61%

Britannia Life Sciences Inc Corporate Events

Britannia Life Sciences Enters $11.3 Million Share Exchange Agreement

Britannia Life Sciences Inc. has entered into an $11.3 million share exchange agreement with McEwen Inc. and Britannia Mining Solutions Inc., marking a significant step in its strategy to unlock value from its portfolio. This transaction enhances Britannia’s position to invest in other cash-generative businesses, potentially increasing returns for shareholders. Additionally, Britannia is extending the closing of its debenture offering to November 30, 2025, as it continues to engage with potential investors.